Abstract:(Mol Ther. 22, 1333–1341; July 2014) The authors have discovered that the original article has errors in Figures 4, S1, and S2 that were introduced when a graduate student used the wrong shared image folder when putting together the figures. In the original Figure 4a, which shows expression of dystrophin-positive fibers in body-wide muscles, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure 4a now appears below. In the original Figure 4d, which shows expression of dystrophin-associated protein complex in quadriceps, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure 4d now appears below. In the original Figure S1a, which shows expression of dystrophin-associated protein complex in quadriceps, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure S1a now appears below. In the original Figures S2a and S2b, a note should be added to the figure legend: the representative control images for C57 and mdx mice shown in Figure 5b are repeated in Figure S2a, and the representative control images for C57 and mdx mice shown in Figure 5a are repeated in Figure S2b. The corrected legend appears below. These corrections do not change the conclusions of the paper. The authors apologize for the errors and any confusion they may have caused.Figure 4dFunctional and phenotypic correction in mdx mice following treatment with M12–PMO conjugates at a single dose of 75 mg/kg intravenouslyView Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S1aFunctional evaluation of skeletal muscles following treatment with M12–PMO conjugates with 3 weekly injections at the dose of 25 mg/kg in mdx miceView Large Image Figure ViewerDownload Hi-res image Download (PPT) Figure S2. Histological and immunological measurement of potential toxicity in mdx mice treated with the M12–PMO conjugate with 3 weekly injections at 25 mg/kgThe representative control images for C57 and mdx mice shown in Figure 5b are repeated in Figure S2a. The representative control images for C57 and mdx mice shown in Figure 5a are repeated in Figure S2b. Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide–Morpholino Conjugate in Dystrophin-Deficient mdx MiceGao et al.Molecular TherapyJuly, 2014In BriefAntisense oligonucleotide (AO)–mediated splice correction therapy for Duchenne muscular dystrophy has shown huge promise from recent phase 2b clinical trials, however high doses and costs are required and targeted delivery can lower both of these. We have previously demonstrated the feasibility of targeted delivery of AOs by conjugating a chimeric peptide, consisting of a muscle-specific peptide and a cell-penetrating peptide, to AOs in mdx mice. Although increased uptake in muscle was observed, the majority of peptide–AO conjugate was found in the liver. Full-Text PDF Open Archive

DG9-conjugated Morpholino Rescues Phenotype in SMA Mice by Reaching the CNS Via a Subcutaneous Administration

Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy.

Systemic antibody-oligonucleotide delivery to the central nervous system ameliorates mouse models of spinal muscular atrophy

Antisense Correction of SMN2 Splicing in the CNS Rescues Necrosis in a Type III SMA Mouse Model.

Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model

Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation

Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA

Peripheral Smn Restoration is Essential for Long-Term Rescue of A Severe Spinal Muscular Atrophy Mouse Model

Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.

Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)

Pharmacological Properties of 2'-O-methoxyethyl-modified Oligonucleotides

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene

Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide

Functional Rescue of Dystrophin-Deficient Mdx Mice by a Chimeric Peptide-PMO

Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264

AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

Myostatin Inhibition in Combination with Antisense Oligonucleotide Therapy Improves Outcomes in Spinal Muscular Atrophy.

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient Mdx Mice

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient <i>mdx</i> Mice (vol 22, pg 1333, 2014)

O.09 Gene therapy of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)